DDR Biomarkers for MDM2 Antagonist Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for reliable biomarkers to predict the effectiveness of cancer treatment using MDM2 antagonists, as current methods struggle to accurately identify which cancer patients will respond to these therapies.
Innovation Solution
The identification of DNA damage response (DDR) pathway genes and their products as biomarkers, specifically focusing on depletion or reduced function in cancer cells, which indicates sensitivity to MDM2 antagonism, allowing for the use of these biomarkers in companion diagnostics and personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complex gene signatures are used to predict cancer sensitivity to MDM2 antagonists, then the predictive capability is improved, but the complexity of the diagnostic test increases
Solution Approach 1:
The patent extracts and focuses on a specific critical biomarker (DDR pathway status, particularly p53 wild-type status and DNA repair deficiency) from among many potential biomarkers. This extraction approach simplifies the diagnostic test by identifying that DDR pathway status is the key determinant of sensitivity to MDM2 antagonists, eliminating the need for complex multi-gene signatures while maintaining predictive accuracy.
2Measurement precision
If multiple gene panel biomarkers are used to predict treatment response, then the accuracy of prediction is improved, but the cost and complexity of testing increases
Solution Approach 1:
The invention identifies and extracts the essential predictive element (DDR pathway status) from complex multi-gene panels. By demonstrating that DDR pathway status alone is sufficient to predict sensitivity to MDM2 antagonists, the patent eliminates the need for expensive and complex multi-gene panel testing while maintaining high prediction accuracy.
3Reliability
If comprehensive molecular profiling is performed to identify therapeutic options, then the ability to identify effective treatments is improved, but the time and resource requirements increase
Solution Approach 1:
The patent extracts the critical predictive information (DDR pathway status) that can be obtained through relatively simple and rapid testing methods. This approach identifies effective treatments much faster than comprehensive molecular profiling by focusing solely on the biomarker that determines sensitivity to MDM2 antagonists, thereby reducing diagnostic time and resource requirements.
Data Source
AI summary
The invention provides DNA damage response (DDR) pathway genes and their gene products as biomarkers to predict effective treatment of cancer using an MDM2 antagonist. Identifying one or more DDR pathway biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an MDM2 antagonist. Accordingly, the invention relates generally to a companion diagnostic for MDM2 antagonist therapy. In particular, the DDR pathway comprises one or more genes from: the homologous recombination repair (HRR) pathway; the non-homologous end joining (NHEJ) pathway; the mismatch repair (MMR) pathway; the Fanconi